Investor SentimentShares remain under pressure on negative sentiment from label expansion setbacks and challenging patient dynamics.
Revenue GuidanceManagement lowered 2024 total revenue guidance to $930 — 980M mainly due to a decrease in its outlook for Daybue.
Sales PerformanceDaybue sales were disappointing, leading to lower 2024 Daybue sales guidance and, consequently, overall 2024 revenue guidance.